Finding novel drugs based on the understanding of a target tissue is called Drug design. Drug design, in its most basic form, is creating molecules that are complementary in charge and shape to the target molecule by which drugs interact and bind. In the big data age, drug design commonly but not always depends on computer modelling methods and bioinformatics strategies. Biopharmaceuticals, particularly therapeutic antibodies, are a class of drugs that are becoming more and more significant in addition to small molecules, and computational methods have made significant strides in enhancing the affinity, selectivity, and stability of these protein-based therapeutics [3]. Preclinical research using animal and cell-based models, human clinical trials, and then the last phase of securing regulatory approval to sell the medicine make up drug development and discovery. The process of modern drug development includes the identification of screening hits, medicinal chemistry, and optimization of those hits to enhance their affinity, efficacy/potency, metabolic stability (to lengthen the half-life), and oral bioavailability. Prior to clinical trials, medication development will start after a molecule that satisfies all of these criteria has been found.
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, Universities of Alberta and Ottawa, Canada
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami, United States
Title : The impact of metal-decorated polymeric nanodots on proton relaxivity
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : R&D consultancy at the medicines discovery catapult: De-risking drug discovery for innovators
Adriana Gambardella, Medicine Discovery Catapult, United Kingdom
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand
Title : Biocompatibility and subcutaneous host response to silk fibroin–chitosan composite plugs: Progress toward biodegradable implant materials
Luis Jesus Villarreal Gomez, Universidad Autónoma de Baja California, Mexico